Angeletti G, Mazzolini M, Rocca A
Department of Respiratory Medicine, Bellaria Hospital, Bologna, Italy.
Respir Med Case Rep. 2022 Dec 13;41:101795. doi: 10.1016/j.rmcr.2022.101795. eCollection 2023.
Relapsing eosinophilic pneumonia and severe eosinophilic asthma are rare and disabling diseases, which share common inflammatory backgrounds and often require long-term systemic steroid therapy. Benralizumab is a humanized antibody targeting IL-5 receptor that reduces corticosteroid dependence and flares up in severe eosinophilic asthma on long term. In this case report, successful treatment of eosinophilic pneumonia and severe eosinophilic asthma with benralizumab is described after a 2-year follow up, showing the promising results of this therapy for eosinophilic pneumonia management.
复发性嗜酸性粒细胞性肺炎和重度嗜酸性粒细胞性哮喘是罕见的致残性疾病，它们具有共同的炎症背景，且常常需要长期的全身性激素治疗。贝那利珠单抗是一种靶向白细胞介素-5受体的人源化抗体，可降低皮质类固醇依赖性，并长期用于重度嗜酸性粒细胞性哮喘的治疗。在本病例报告中，描述了使用贝那利珠单抗对嗜酸性粒细胞性肺炎和重度嗜酸性粒细胞性哮喘进行成功治疗并随访2年的情况，显示了该疗法在嗜酸性粒细胞性肺炎治疗方面的良好前景。
